Cargando…
The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored
Alzheimer’s disease (AD), the most common cause of dementia, results in a sustained decline in cognition. There are currently few effective disease modifying therapies for AD, but insights into the mechanisms that mediate the onset and progression of disease may lead to new, effective therapeutic st...
Autores principales: | Chandra, Sidhanth, Sisodia, Sangram S., Vassar, Robert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889249/ https://www.ncbi.nlm.nih.gov/pubmed/36721148 http://dx.doi.org/10.1186/s13024-023-00595-7 |
Ejemplares similares
-
Halogenation in Fungi: What Do We Know and What Remains to Be Discovered?
por: Cochereau, Bastien, et al.
Publicado: (2022) -
The gut microbiome regulates astrocyte reaction to Aβ amyloidosis through microglial dependent and independent mechanisms
por: Chandra, Sidhanth, et al.
Publicado: (2023) -
Hepatitis B Treatment: What We Know Now and What Remains to Be Researched
por: Suk‐Fong Lok, Anna
Publicado: (2018) -
What We Know and What Remains to Be Explored about LGBTQ Parent Families in Israel: A Sociocultural Perspective
por: Shenkman, Geva, et al.
Publicado: (2022) -
COVID-19 Imaging: What We Know Now and What Remains Unknown
por: Kanne, Jeffrey P., et al.
Publicado: (2021)